Abstract
Missense “hotspot” mutations localized in six p53 codons account for 20% of TP53 mutations in human cancers. Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether and how they may gain additional functions promoting tumorigenesis remain controversial. Here we generated Trp53Y217C, a mouse model of the human hotspot mutant TP53Y220C. DNA damage responses were lost in Trp53Y217C/Y217C cells, and Trp53Y217C/Y217C fibroblasts exhibited increased chromosome instability compared to Trp53-/- cells. Furthermore, Trp53Y217C/Y217C male mice died earlier than Trp53-/- males, with more aggressive thymic lymphomas. This correlated with an increased expression of inflammation-related genes in Trp53Y217C/Y217C thymic cells compared to Trp53-/- cells. Surprisingly, we recovered only one Trp53Y217C/Y217C female for 22 Trp53Y217C/Y217C males at weaning, a skewed distribution explained by a high frequency of Trp53Y217C/Y217C female embryos with exencephaly and the death of most Trp53Y217C/Y217C female neonates. Strikingly however, when we treated pregnant females with the anti-inflammatory drug supformin (LCC-12) we observed a five-fold increase in the proportion of viable Trp53Y217C/Y217C weaned females in their progeny. Together, these data suggest that the p53Y217C mutation not only abrogates wildtype p53 functions but also promotes inflammation, with oncogenic effects in males and teratogenic effects in females.
Introduction
Somatic alterations in the TP53 gene, encoding the tumor suppressor p53, are the most common events in human tumors (Hollstein et al., 1991). The p53 protein is a stress sensor stabilized and activated in response to potentially oncogenic insults. In its tetrameric active form, wildtype (WT) p53 can trigger a transcriptional program to induce various responses including cell cycle arrest, senescence, apoptosis or metabolic changes (Beckerman and Prives, 2010). In human cancers, about 75% of all TP53 alterations are missense mutations, and the eight most frequent (“hotspot”) missense mutations (R175H, Y220C, G245S, R248Q, R248W, R273H, R273C and R282W) affect six residues localized in the p53 DNA-binding domain (DBD) and account for 20% of all TP53 mutations (Hainaut and Pfeifer, 2016). The fact that most TP53 mutations are missense substitutions suggested that cells expressing mutant p53 might have a selective advantage over cells lacking p53, and evidence for this was first gained by expressing various p53 mutants in p53-null cells and observing enhanced tumorigenic potential in nude mice or increased plating efficiency in agar cell culture (Dittmer et al., 1993). Mouse models expressing hotspot p53 mutants next helped to define potential mechanisms accounting for accelerated tumorigenesis. First, a dominant-negative effect (DNE) may be observed in heterozygotes, if the mutant p53 inhibits the WT p53 protein in hetero-tetramers (Gencel-Augusto and Lozano, 2020). Evidence that this mechanism accounts for accelerated tumorigenesis was notably reported in human leukemia (Boettcher et al., 2019). A second mechanism is a gain-of-function (GOF), i.e. the acquisition by mutant p53 of new oncogenic properties (Amelio and Melino, 2020; Stein et al., 2020). Although the DNA sequence specificity of p53 mutants is impaired, leading to a loss of WT functions (LOF), many p53 mutant proteins are stabilized in the cell and might engage in aberrant interactions with other transcription factors, chromatin-modifying complexes or DNA helicase subunits, leading to the acquisition of GOF phenotypes (Kim and Deppert, 2007; Pfister and Prives, 2017; Zhao et al., 2024). However, a few recent studies challenged the pathological importance of mutant p53 GOF, or at least its relevance in anti-cancer therapeutic strategies (Aubrey et al., 2018; Boettcher et al., 2019; Wang et al., 2023). An alternative hypothesis emerged, postulating that the tumorigenic properties of a p53 mutant might result from a separation-of-function (SOF), if the mutant retains pro-proliferative or pro-survival functions of WT p53 while losing its tumor suppressive activities (Kennedy and Lowe, 2022). The concept of SOF was first proposed for TP53 exon-6 truncating mutations, which mimic a naturally occurring alternative p53 splice variant (Shirole et al., 2016), but may apply to some p53 missense mutations, for example p53R248W (Humpton et al., 2018). Importantly, the analysis of various mutant p53 alleles in vivo appears crucial for a better understanding of their contribution to tumorigenesis, because GOF/SOF phenotypes may vary depending on the mutated residue, its specific mutation, the cellular context or genetic background (Dibra et al., 2024; Hanel et al., 2013; Kadosh et al., 2020; Kim and Lozano, 2018; Kotler et al., 2018; McCann et al., 2022; Xiong et al., 2022).
In human cancers, the TP53Y220C mutation is the most frequent missense mutation outside of the DNA-binding surface of p53 (Hainaut and Pfeifer, 2016). The somatic TP53Y220C mutation accounts for over 100,000 new cancer cases per year worldwide, including solid tumors and myeloid neoplasms, and a germline TP53Y220C mutation was reported in 15 families with the Li-Fraumeni syndrome (LFS) of cancer predisposition (Bouaoun et al., 2016; Gener-Ricos et al., 2024). The mutation causes a structural change in the DBD localized at the periphery of the β-sandwich region of the protein, far from the surface contact of DNA. The mutation from a tyrosine to a cysteine markedly lowers the thermodynamic stability of the DBD, leading to a largely unfolded and inactive protein at body temperature (Joerger et al., 2006), and a molecule designed to bind p53Y220C and restore WT protein conformation appears as a promising anti-cancer drug (Dumbrava et al., 2022). Analyses of the impact of p53Y220C in cancer cell lines led to conflicting results. On one hand, overexpression of p53Y220C in a p53-null cell line increased its capacity for migration or invasion (Zhou et al., 2022), and a decreased expression of p53Y220C, caused by RNA interference or various chemical compounds, promoted cell death or decreased the migratory or invasive capacities of cells (Tseng et al., 2022; Vikhanskaya et al., 2007; Zhou et al., 2022). On the other hand, the removal by CRISPR/Cas9 of p53 mutants with reported GOF - including p53Y220C - in diverse cancer cell lines had no significant impact on cell survival or proliferation, and the cell death caused by RNA interference against p53Y220C might result from non-specific toxic effects (Wang et al., 2023). Here, to gain a better understanding of the impact of the p53Y220C mutation in vivo, we generated a mouse model with a targeted Trp53Y217C mutation - the mouse equivalent to human TP53Y220C (Figure S1) - and analyzed animals and cells carrying one or two copies of the mutant allele.
Results
Targeting of a p53Y217C mutation in the mouse
We used homologous recombination in 129/SvJ ES cells to target the p53Y217C mutation at the mouse Trp53 locus. Mice expressing p53Y217C conditionally were generated by using a targeting vector containing transcriptional stops flanked by LoxP sites (LSL) upstream of coding sequences, and the p53Y217C mutation in exon 6 (Figure 1A-D). Trp53+/LSL-Y217C mice were then crossed with mice carrying the PGK-Cre transgene (Lallemand et al., 1998) to excise the LSL cassette and obtain Trp53+/Y217C mice, expressing the mutant protein constitutively. After two backcrosses over a C57BL/6J background, we prepared mouse embryonic fibroblasts (MEFs) from intercrosses of Trp53+/Y217C mice (Figure 1E). We extracted RNAs from Trp53Y217C/Y217C MEFs then sequenced p53 mRNAs to verify that the p53Y217C coding sequence was identical to the wildtype p53 (p53WT) sequence, except for the desired missense mutation and a silent mutation introduced to facilitate mouse genotyping (Figure 1F). The quantification of p53 mRNA levels from WT and Trp53Y217C/Y217C MEFs next revealed similar transcription from both alleles (Figure 1G).

Targeting the Y217C missense mutation at the mouse Trp53 locus.
(A) Targeting strategy. The wildtype (WT) Trp53 gene is within a 17 kb-long EcoRI (RI) fragment (black boxes are for coding sequences and white boxes for UTRs). The targeting construct contains: (1) a 1.5 kb-long 5’ homology region; (2) a Lox-Stop-Lox (LSL) cassette with a neomycin selection gene (Neo), four transcriptional stops (STOP) and an EcoRI site, flanked by LoxP sites (arrowheads); (3) p53 coding exons, including the Y217C (YC) missense mutation in exon 6 (asterisk) and an additional BanII site; (4) a 2.8 kb-long 3’ homology region; and (5) the diphteria α-toxin (DTA) gene for targeting enrichment. Proper recombinants with a Trp53LSL-Y217C allele, resulting from the described crossing-overs, were G418 resistant. They were identified by a 2.4 kb-long band after PCR with primers a and b, and confirmed by bands of 635 and 224 bp after PCR with primers c and d and BanII digestion. They were also verified by Southern blot with the indicated probe as containing a 10.5 kb EcoRI band. Two recombinant ES clones were injected into blastocysts to generate chimeras, and germline transmission was verified by genotyping with primers c and d and BanII digestion. Excision of the LSL cassette was performed in vivo, by breeding Trp53+/LSL-Y217C male mice with females carrying the PGK-Cre transgene, to obtain mice with a Trp53Y217C allele. (B-D) Screening of recombinant ES clones (+) by PCR with primers a and b (B); PCR with primers c and d then BanII digestion (C); Southern blot (D). (E) Genotyping of mouse embryonic fibroblasts (MEFs) from an intercross of Trp53+/Y217C mice, by PCR with primers c and d and BanII digestion. (F) Trp53Y217C sequence around codon 217. The introduced Y217C missense mutation and the silent mutation creating an additional BanII restriction site are highlighted (asterisks). (G) WT and Trp53Y217C/Y217C (YC/YC) MEFs express similar p53 mRNA levels. Total RNA was extracted, then p53 mRNAs were quantified by real-time qPCR, normalized to control mRNAs and the amount in WT cells was assigned the value of 1. Primer sequences are listed in Table S8.
Deficient p53-dependent stress responses in Trp53Y217C/Y217C cells
We used western blots to analyze protein extracts from Trp53+/+, Trp53+/-, Trp53+/Y217C, Trp53Y217C/Y217C and Trp53-/- MEFs, unstressed or treated with Nutlin, an antagonist of Mdm2, the E3 ubiquitin ligase for p53 (Vassilev et al., 2004). Results indicated a high increase in p53 abundance in untreated and Nutlin-treated Trp53Y217C/Y217C MEFs and a moderate increase in untreated and Nutlin-treated Trp53+/Y217C MEFs, compared to WT cells (Figures 2A and S2). Protein levels for p21 and Mdm2, the products of two classical p53 target genes, appeared similar in Trp53+/+ and Trp53+/Y217C MEFs, and were undetectable or markedly decreased in Trp53Y217C/Y217C and Trp53-/- MEFs (Figures 2A and S2). Accordingly, p53Y217C appeared unable to transactivate the Cdkn1a/p21 and Mdm2 genes or to bind their promoters (Figure 2B). The fractionation of cells before or after treatment with doxorubicin, a clastogenic drug, indicated that p53WT accumulated in the nucleoplasm and chromatin fractions in response to DNA damage, whereas p53Y217C appeared mostly cytoplasmic in both untreated and doxorubicin-treated cells, and undetectable or barely detectable in chromatin fractions (Figures 2C and S3). Furthermore, when Nutlin-treated MEFs were analyzed by immunofluorescence, p53WT was only detected in nuclei, whereas p53Y217C could be observed in nuclear and cytoplasmic compartments (Figure 2D). We next analyzed two well-known p53-mediated responses to DNA damage, i.e. cell cycle arrest in MEFs and apoptosis in thymocytes (Kastan et al., 1992; Lowe et al., 1993). WT MEFs exposed to increasing doses of ɣ-irradiation (3 Gy or 12 Gy) exhibited significant increases in G1/S ratios, whereas G1/S ratios were similar before or after irradiation in Trp53Y217C/Y217C and Trp53-/- MEFs (Figures 2E and S4). Furthermore, thymocytes recovered from irradiated WT mice underwent a massive apoptotic response, with an almost three-fold increase in apoptotic cells after a 10 Gy irradiation. By contrast, no increase in apoptotic cells was observable upon irradiation in the thymi from Trp53Y217C/Y217C mice, and apoptotic thymocytes were equally rare in irradiated Trp53Y217C/Y217C and Trp53-/- mice (Figures 2F and S5). Together, these results indicated that the p53Y217C mutation altered the abundance and intracellular distribution of the p53 protein, associated with a decrease in DNA-bound protein, and that p53Y217C had completely lost the ability to induce cell cycle arrest and apoptosis upon DNA damage.

Trp53Y217C/Y217C cells exhibit alterations in p53 abundance and subcellular localization, defective responses to DNA damage, and increased chromosomal instability.
(A) Increased p53 protein levels in Trp53Y217C/Y217C and Trp53+/Y217C MEFs. MEFs of the indicated genotypes were treated or not with 10 μM Nutlin 3a for 24 h, then protein extracts were immunoblotted with antibodies against Mdm2, p53, p21 and actin. (B) The transactivation of classical p53 target genes Cdkn1a/p21 and Mdm2 is impaired in Trp53Y217C/Y217C cells. WT, Trp53Y217C/Y217C and Trp53-/- MEFs were treated as in (A), then (top) mRNAs were quantified in 5-6 independent experiments using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in unstressed WT cells assigned a value of 1; or (bottom) ChIP assays were performed at the Cdkn1a and Mdm2 promoters in 2-3 independent experiments with an antibody against p53 or rabbit IgG as a negative control. Immunoprecipitates were quantified using real-time PCR, normalized to data over an irrelevant region, and the amount in unstressed WT cells was assigned a value of 1. (C) Assessment of p53WT and p53Y217C subcellular localization by cellular fractionation. WT and Trp53Y217C/Y217C MEFs were treated or not with 1 μM doxorubicin (Doxo) for 24 hr, submitted to cellular fractionation, then protein extracts were immunoblotted with antibodies against p53 or the fraction controls Tubulin for cytoplasm (Cp.), Nup98 for nucleoplasm (Np.) and histone H3 for chromatin (χin). (D) Assessment of p53WT and p53Y217C subcellular localization by immunofluorescence. WT, Trp53Y217C/Y217C and Trp53-/- MEFs were treated with 10 μM Nutlin 3a for 24 h, then stained with antibodies against p53 (red) or actin (green) and DNA was counterstained with DAPI (blue). (E) Absence of a cell cycle arrest response in Trp53Y217C/Y217C MEFs. Asynchronous cell populations of Trp53+/+, Trp53Y217C/Y217C and Trp53-/- MEFs were analyzed 24 hr after 0, 3 or 12 Gy ɣ-irradiation. Results from 3 independent experiments. (F) Absence of a p53-dependent apoptotic response in Trp53Y217C/Y217C thymocytes. Age-matched mice of the indicated genotypes were left untreated or submitted to 10 Gy whole-body ɣ-irradiation then sacrificed after 4 hr and their thymocytes were stained with Annexin V-FITC and analyzed by FACS, in 2 independent experiments. (G) Increased chromosomal instability in Trp53Y217C/Y217C fibroblasts. Metaphase spreads were prepared from WT, Trp53Y217C/Y217C and Trp53-/- MEFs at passage 4, then aberrant metaphases (with chromosome breaks, radial chromosomes or DMs) were scored. Left: distribution of aberrant metaphases. Data from 110 WT, 97 Trp53Y217C/Y217C or 119 Trp53-/- complete diploid metaphases, independently observed by two experimenters. Right: examples of two aberrant Trp53Y217C/Y217C metaphases: one with a double minute chromosome (DM), a chromosome break (Br) and a radial chromosome (R), the other with multiple DMs. Enlargements of regions of interest are presented between the two metaphases. Scale bars (D, G): 5 μm. ***P<0.001, **P<0.01, *P<0.05, °P=0.09, ns: non-significant by Student’s t (B, E, F) or Fischer’s (G) tests.
Increased chromosomal instability in Trp53Y217C/Y217C cells
We next searched for evidence, at the cellular level, of potential dominant negative effect (DNE) or gain of function (GOF) for the p53Y217C mutant. Little if any difference in the transactivation of canonical p53 target genes was observed between WT, Trp53+/Y217C and Trp53+/- cells treated with Nutlin or Doxorubicin (Figure S6A), and Trp53+/Y217C and Trp53+/- cells exhibited similar cell cycle arrest or apoptotic responses to γ-irradiation (Figure S6B-C), suggesting little or no DNE in response to various stresses.
On the opposite, we obtained clear evidence of a GOF for the p53Y217C mutant. Two p53 mutants (p53G245D and p53R273H) were recently proposed to promote tumorigenesis by predisposing cells to chromosomal instability (Zhao et al., 2024), which led us to compare the frequency of chromosome rearrangements in WT, Trp53Y217C/Y217C and Trp53-/- primary MEFs. We searched for chromosome breaks, radial chromosomes, or double-minute chromosomes (DMs) in preparations of MEFs treated with the anti-mitotic nocodazole for metaphase enrichment. The three categories of chromosome rearrangements were more frequently observed in Trp53Y217C/Y217C MEFs than in Trp53-/- or WT cells (Figure 2G), indicating a GOF that promotes chromosomal instability.
Impact of p53Y217C on mouse development
We next determined the impact of the p53Y217C mutation in vivo, by comparing mouse cohorts generated from intercrosses of heterozygous Trp53+/- or Trp53+/Y217C mice resulting from ≥ 5 backcrosses to the C57BL6/J background. Intercrosses of Trp53+/- mice are known to yield a reduced proportion of Trp53-/- mice, that is mainly due to defects in neural tube closure causing exencephaly in a fraction of Trp53-/- female embryos (Armstrong et al., 1995; Sah et al., 1995) and, to a lesser extent, to lung dysfunction affecting a fraction of Trp53-/- neonates (Tateossian et al., 2015). At weaning (on the 21st day postpartum or P21), we observed one Trp53-/- female mouse for 3.5 p53-/- males from Trp53+/- intercrosses, an underrepresentation of females consistent with frequencies reported in earlier studies (Armstrong et al., 1995; Sah et al., 1995). Strikingly, the underrepresentation of weaned females was even more acute for Trp53Y217C/Y217C mice, with only one Trp53Y217C/Y217C female for 19 Trp53Y217C/Y217C males from Trp53+/Y217C intercrosses (Figure 3A). We next analyzed Trp53Y217C/Y217C embryos generated from heterozygous intercrosses or from heterozygous-homozygous (Trp53+/Y217C x Trp53Y217C/Y217C) crosses, at embryonic days E12.5-E16.5. An underrepresentation of Trp53Y217C/Y217C female embryos was not observed, but 11/26 (42%) female embryos exhibited developmental abnormalities, including 10 with exencephaly, whereas all the male embryos appeared normal (Figure 3B). Importantly, the frequency of Trp53Y217C/Y217C female embryos with exencephaly (38.5%) was much higher than the reported frequency (0-8%) of Trp53-/- female embryos with exencephaly of C57BL/6 x 129/Sv genetic background (Donehower et al., 1992; Sah et al., 1995), suggesting a stronger effect of the p53Y217C mutant on female embryonic development.

Trp53Y217C/Y217C mice exhibit female-specific perinatal lethality.
(A) Distribution of weaned mice obtained from Trp53+/- or Trp53+/Y217C intercrosses. Obs: observed numbers of mice at weaning (P21); exp: expected numbers assuming a Mendelian distribution without sex distortion; f/m: observed female/male ratios. Consistent with previous reports, the observed distribution of weaned mice from Trp53+/- intercrosses did not conform to values expected for a Mendelian distribution without sex distortion (υ=5; χ2=16.31>15.09), indicating a significant deficit in female Trp53-/- mice (top). The distribution of weaned mice from Trp53+/Y217C intercrosses diverged even more from values for a Mendelian distribution without sex distortion (υ =5; χ2=104.23>15.09), due to a striking deficit in female Trp53Y217C/Y217C mice (bottom). Differences between the frequencies of Trp53Y217C/Y217C (4/677) and Trp53-/- (8/196) females in the progeny, or between the female to male ratios for Trp53Y217C/Y217C (4/75) and Trp53-/- (8/28) animals, are statistically significant (P=0.0012 and P=0.0087 in Fischer’s tests, respectively). (B) Exencephaly is frequently observed in p53Y217C/Y217C female embryos. Top: the distribution of E12.5-16.5 embryos from heterozygous (Trp53+/Y217C) intercrosses or heterozygous-homozygous (Trp53+/Y217C x Trp53Y217C/Y217C) crosses is shown. f or m exenc.: number of female or male embryos with exencephaly; o.a.: embryos with other abnormalities. Below, examples of female Trp53Y217C/Y217C embryos at E12.5, 13.5 and 16.5 exhibiting exencephaly (arrows) are each shown (center) together with a normal embryo from the same litter (bottom). (C) Distribution of mice at birth from the indicated crosses. Of note, out of five Trp53Y217C/Y217C females observed at birth, only one remained alive at weaning age. Thus, the female/male ratio for weaned Trp53Y217C/Y217C animals from these crosses was 1/22, a ratio similar to the one observed in A (4/75).
In Trp53-/- female mice, exencephaly was previously correlated with stochastic aberrant X chromosome inactivation, with a decreased expression of Xist and an increase in bi-allelic expression of X-linked genes including Maob, Pls3 and Usp9x (Delbridge et al., 2019). We prepared neurospheres from Trp53+/+, Trp53-/- and Trp53Y217C/Y217C female embryos and quantified mRNAs for these genes in neurospheres. Compared to neurospheres from WT animals, Trp53Y217C/Y217C and Trp53-/- neurospheres exhibited an apparent decrease in Xist expression and significantly higher levels of Maob, Pls3 and Usp9x (Figure S7). Thus, as for female Trp53-/- mice, aberrant chromosome X inactivation may contribute to the underrepresentation of Trp53Y217C/Y217C female mice. Of note however, defects in chromosome X inactivation did not appear more pronounced in Trp53Y217C/Y217C neurospheres than in Trp53-/- neurospheres.
To further analyze the impact of the p53Y217C mutation during development, we also determined its potential effect in embryos lacking Mdm2 or Mdm4, two major p53 regulators. The embryonic lethality resulting from Mdm2 or Mdm4 loss is rescued by a concomitant p53 deficiency (Bardot et al., 2015; Finch et al., 2002; Jones et al., 1995; Migliorini et al., 2002; Montes de Oca Luna et al., 1995; Parant et al., 2001). This provides a powerful assay for analyzing the functionality of p53 mutant alleles (Bardot et al., 2015; Iwakuma et al., 2004; Marine et al., 2006; Toledo et al., 2006). We identified Mdm2-/- Trp53Y217C/Y217C and Mdm4-/- Trp53Y217C/Y217C viable mice of both sexes, consistent with a major loss of canonical WT p53 activities in the p53Y217C mutant (Table S1). Of note, in these experiments we mated Mdm4+/- Trp53+/Y217C mice with Mdm4+/- Trp53Y217C/Y217C mice, or Mdm2+/- Trp53+/Y217C mice with either Mdm2-/- Trp53Y217C/Y217C or Mdm2+/- Trp53Y217C/Y217C animals, to analyze the progeny at weaning. No Trp53Y217C/Y217C female mouse was recovered from these crosses, whereas 14 Trp53Y217C /Y217C males were obtained, again demonstrating a striking deficit in Trp53Y217C/Y217C females at weaning. Among animals lacking one or two copies of either Mdm2 or Mdm4, we also observed a deficit in Trp53Y217C/Y217C weaned females. However, the female to male ratio for Trp53Y217C/Y217C animals appeared markedly increased in genetic backgrounds with Mdm4 haploinsufficiency (4/15) or loss (1/6), but only marginally increased (if at all) in genetic backgrounds with Mdm2 haploinsufficiency (1/11) or loss (1/11). This suggested that altering the levels of p53 inhibitors, particularly Mdm4, might improve the survival of Trp53Y217C/Y217C females (Table S1).
The high frequency (42%) of abnormal Trp53Y217C/Y217C female embryos at E12.5-E16.5 could only partially account for the acute deficit in Trp53Y217C/Y217C females observed at weaning, suggesting either embryonic abnormalities undetectable macroscopically, or that a fraction of Trp53Y217C/Y217C females died later in development or postpartum. We performed additional crosses to analyze female to male ratios at postpartum day 0 or 1 (P0-P1) and observed 20 females for 18 males for Trp53+/+ animals, but only five females for 22 males for Trp53Y217C/Y217C animals (Figure 3C). Furthermore, only one of these Trp53Y217C/Y217C females reached weaning age, and the four other neonates died before P2. Altogether, these data led to conclude that the p53Y217C mutation caused female-specific developmental abnormalities at a higher penetrance than a null allele, leading to a perinatal (late embryonic or early postpartum) lethality for most homozygous mutant females.
Interestingly, we observed that Trp53Y217C/Y217C males were fertile and included them in some of our crosses to generate homozygous mutants at higher frequencies (Figure 3B-C). By contrast, we were able to mate two Trp53Y217C/Y217C adult females with a Trp53+/Y217C male, and both got pregnant but had to be euthanized due to complications while giving birth. In both cases, extended labor (> 24 hr) was the main sign of dystocia (Table S2). These observations suggest that, even for the rare Trp53Y217C/Y217C females able to reach adulthood, the p53Y217C mutation caused pathological traits not observed in Trp53-/- females, because the loss of p53 was not previously reported to cause dystocia (Embree-Ku and Boekelheide, 2002; Guimond et al., 1996; Hu et al., 2007). Together, our data indicated that the p53Y217C mutation not only abolished canonical p53 activities, but also conferred additional effects compromising female perinatal viability or parturition.
Impact of p53Y217C on tumorigenesis
We next analyzed the impact of the p53Y217C mutation on the onset and spectrum of spontaneous tumors in mice. We first compared Trp53+/Y217C, Trp53+/- and Trp53+/+ mouse cohorts for 2 years. Trp53+/Y217C and Trp53+/- cohorts exhibited similar spontaneous tumor onset and spectrum, with most mice developing sarcomas during their second year of life (Figure S8). Thus, at least for tumors arising spontaneously, the p53Y217C mutant protein did not appear to exert a DNE over the wildtype p53 protein.
We next compared Trp53Y217C/Y217C and Trp53-/- mouse cohorts. Because of the difficulty to generate Trp53Y217C/Y217C females, we restricted our comparison to males, to avoid potential biases that might result from different sex ratios. All Trp53-/- mice are known to die in less than 1 year, from thymic lymphomas in most cases, or more rarely from sarcomas (Donehower et al., 1992; Jacks et al., 1994). Trp53Y217C/Y217C males died faster than their Trp53-/- counterparts: all the Trp53Y217C/Y217C males were dead by the age of 7 months, whereas more than 20% of the Trp53-/- males were still alive at that age (Figure 4A). Furthermore, most Trp53-/- and Trp53Y217C/Y217C mice died from thymic lymphomas, but histological analysis of tumor organs revealed that the lymphomas in Trp53Y217C/Y217C males were more aggressive and invasive, with sites of metastases notably including the lungs, spleen, liver or kidneys (Figures 4B-C and S9). Thus, the p53Y217C mutation not only abolished canonical tumor suppressive activities but also apparently conferred oncogenic properties to the encoded protein. Consistent with this, when we performed an RNA-seq analysis of thymi from 8 weeks-old Trp53+/+, Trp53-/- and Trp53Y217C/Y217C males, 81.5 % of the 717 differentially expressed genes indicated a loss of function (LOF) in the p53Y217C mutant, but genes suggesting a GOF or a separation of function (SOF) were also observed (Figure S10A and Table S3). Of note, among the differentially expressed genes corresponding to a LOF in the p53Y217C mutant were Bbc3/Puma, Cdkn1a/p21 and Zmat3 (Figure S10B), three p53-target genes known to play major roles in p53-mediated tumor suppression (Brennan et al., 2023).

Oncogenic effects of the mutant protein in Trp53Y217C/Y217C male mice.
(A-B) In homozygous males, p53Y217C leads to accelerated tumor-induced death (A), and aggressive metastatic tumors (B); n=cohort size. (C) Hematoxylin and eosin (H&E) staining of sections from the lung (top) and spleen (bottom) of Trp53-/- and Trp53Y217C/Y217C male mice, showing metastases in Trp53Y217C/Y217C animals. Normal organ structures are shown, with “A” indicating pulmonary alveoli, and “WP” and “RP” standing for splenic white and red pulp, respectively. In the lung section of the Trp53Y217C/Y217C mouse, the rectangle indicates a lymphoma area. In the spleen section of the Trp53Y217C/Y217C mouse, the typical splenic structures are absent due to massive tissue homogenization of the spleen by lymphoma cells.
We next performed a comparative analysis focusing on Trp53Y217C/Y217C and Trp53-/- thymi, which revealed 192 differentially expressed genes (Figure 5A-B and Table S4). An analysis of these data with GOrilla, the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (Eden et al., 2009), indicated that 141 of these genes were associated with at least one gene ontology (GO) term, and revealed a significant enrichment for genes associated with white blood cell chemotaxis/migration and inflammation (Figures 5C and S11). Among these genes were notably Ccl17, Ccl9, Ccr3, Cxcl10, S100a8 and S100a9, six genes associated each with 10-15 GO terms related to white blood cell behavior and inflammation (Table S5). We next used RT-qPCR to quantify the expression of these genes in thymi from 8 weeks-old Trp53+/+, Trp53Y217C/Y217C and Trp53-/- male mice. Their expression was significantly increased in Trp53Y217C/Y217C thymic cells compared to Trp53-/-, or to both Trp53+/+ and Trp53-/- cells, consistent with gain or separation of function (GOF/SOF) effects in the Trp53Y217C mutant (Figure 5D). We also compared the transcriptomes of Trp53Y217C/Y217C and Trp53-/- thymocytes by gene set enrichment analysis (Subramanian et al., 2005). We found 13 gene sets significantly enriched in Trp53Y217C/Y217C cells with normalized enrichment scores (NES) > 2, among which three (“antimicrobial peptides”, “chemokine receptors bind chemokines” and “defensins”) were related to immunity (Figures 5E and S12A), consistent with an inflammatory response associated with the p53Y217C mutant. Other enriched gene sets notably included five sets (“electron transport chain”, “respiratory electron transport ATP synthesis by chemiosmotic coupling and heat production by uncoupling proteins”, “mitochondrial translation”, “respiratory electron transport” and “oxidative phosphorylation”) related to mitochondria function, and three sets (“deposition of new CENPA-containing nucleosomes at the centromere”, “arginine methyltransferases methylate histone arginines” and “PRC2 methylates histones and DNA”) related to chromatin plasticity (Figures 5E and S12B-C). These gene sets, differentially expressed between Trp53Y217C/Y217C and Trp53-/- cells, might contribute to accelerated tumorigenesis in Trp53Y217C/Y217C mice, given the reported impact of inflammation, metabolism changes and epigenetic plasticity on cancer evolution (Feinberg et al., 2006; Greten and Grivennikov, 2019; Kroemer and Pouyssegur, 2008). Furthermore, the hotspot mutants p53G245D or p53R273H were recently proposed to promote tumor progression by inducing non-canonical nuclear factor kappa light chain enhancer of activated B cell (NC-NF-κB) signaling (Zhao et al., 2024). In Trp53Y217C/Y217C cells, one gene set related to NC-NF-κB (“Dectin 1-mediated non-canonical NF-κB signaling”) was significantly enriched and two other NF-κB-related gene sets were also potentially enriched (Figure 5F and S13).

Evidence of inflammation in Trp53Y217C/Y217C mice.
(A-B) RNAseq analysis of thymi from Trp53Y217C/Y217C (n=3) and Trp53-/- (n=3) 8 weeks-old male mice. Volcano plot (A), with differentially expressed genes (DEGs), downregulated (blue) or upregulated (red) in Trp53Y217C/Y217C cells. Unsupervised clustering heat-map plot (B), with 192 DEGs ranked according to log2 fold changes. (C) Gene Ontology (GO) analysis of DEGs. Out of 192 DEGs, 141 are associated with at least one GO term, according to the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla). For each GO term, enrichment was calculated by comparing with the full list of 19759 genes associated with a GO term, and results are presented here with a color scale according to P-value of enrichment. This analysis mainly revealed an enrichment for genes associated with white blood cell chemotaxis/migration and inflammation, as shown here. Complete results of the analysis are presented in Figure S11. (D) RT-qPCR analysis of the indicated genes in thymi from 8 weeks-old Trp53+/+, Trp53Y217C/Y217C and Trp53-/- male mice. Means + s.e.m. (n=3 per genotype). ***P<0.001, **P<0.01, *P<0.05, °P<0.075 by Student’s t test. (E) Gene set enrichment analysis (GSEA) of transcriptomes from Trp53Y217C/Y217C and Trp53-/- thymic cells. GSEA identified 13 gene sets enriched in Trp53Y217C/Y217C cells with normalized enrichment scores (NES) > 2. Nominal p-values (NOM p-val) and false discovery rate q-values (FDR q-val) are indicated. (F) GSEA provides evidence of increased NC-NF-kB signaling in Trp53Y217C/Y217C male thymocytes. Results are presented as in E. (G) Supformin (LCC-12), an anti-inflammatory molecule, increases the female to male ratio in Trp53Y217C/Y217C weaned pups. Trp53+/Y217C females were mated with Trp53Y217C/Y217C males, then oral gavage of pregnant females with 5 mg/kg supformin was performed on the 10th and 11th days post-coitum, and their progeny was genotyped at weaning. The female to male (f/m) ratio for Trp53Y217C/Y217C weaned pups that were exposed to supformin in utero (+) was compared to the f/m ratios for Trp53-/- or Trp53Y217C/Y217C weaned pups never exposed to supformin (-). Exposure to supformin led to a five-fold increase in the proportion of Trp53Y217C/Y217C weaned females. **P<0.01, °P=0.056, ns: non-significant by Fischer’s test.
Reducing inflammation may rescue a fraction of female Trp53Y217C/Y217C embryos
Our data indicated that inflammation correlated with accelerated tumorigenesis in Trp53Y217C/Y217C male mice. Interestingly, inflammation was previously proposed to promote neural tube defects or embryonic death in a few mouse models (Lian et al., 2004; McNairn et al., 2019; Zhao et al., 2013). Furthermore CD44, encoding a cell-surface glycoprotein that drives inflammation and cancer progression (Solier et al., 2023), was recently identified as a key gene for the diagnosis and early detection of open neural tube defects (Karthik et al., 2022). Together, these data led us to hypothesize that, at least in a fraction of Trp53Y217C/Y217C females, neural tube defects might result from inflammation. To test this hypothesis, we mated Trp53+/Y217C female mice with Trp53Y217C/Y217C males, then administered supformin to pregnant females by oral gavage. Supformin (LCC-12), a potent inhibitor of the CD44-copper signaling pathway, was shown to reduce inflammation in vivo (Solier et al., 2023). Without any treatment, our previous crosses (Figure 3 and Table S1) collectively yielded a female to male ratio of 0.045 for Trp53Y217C/Y217C weaned mice (f/m=5/111 [4+1+0+0]/[75+22+9+5]), significantly different from the ratio of 0.29 (f/m=8/28) for Trp53-/- weaned animals. By contrast, in the progeny of supformin-treated pregnant mice we observed a five-fold increase in the female to male ratio for Trp53Y217C/Y217C weaned animals, to reach a value of 0.23 (f/m=3/13) indistinguishable from the ratio in Trp53-/- weaned animals from untreated mice (Figure 5G and Table S6). This result suggests that reducing inflammation in developing Trp53Y217C/Y217C female embryos may increase their viability.
Discussion
In this report, we generated a mouse model with a Trp53Y217C allele, the murine equivalent of the human hotspot mutant TP53Y220C. The analysis of this mouse model indicated that the p53Y217C mutation leads to the loss of many canonical wildtype p53 activities, notably the capacity to transactivate target genes important for tumor suppression (e.g. Bbc3, Cdkn1a and Zmat3). The fact that p53Y217C can rescue the embryonic lethality caused by a deficiency in Mdm2 or Mdm4 is also consistent with a major loss of canonical wildtype p53 functions (LOF) in this mutant. These findings are consistent with the notion that hotspot p53 mutants cause a complete or near complete LOF (Funk et al., 2025).
In addition, our analyses provide evidence that the p53Y217C mutation exhibits oncogenic effects. The possibility that a mutant p53 might acquire oncogenic functions was first suggested over 30 years ago (Dittmer et al., 1993), but this notion became controversial in recent years. Indeed, studies of a few p53 mutants in human acute myeloid leukemia and a mouse model of B cell lymphoma indicated that their increased tumorigenicity might result from dominant-negative effects (DNE) rather than gain of function (GOF), and a recent study further suggested that the putative GOF of many p53 mutants would not be required to sustain the expansion of tumors (Aubrey et al., 2018; Boettcher et al., 2019; Wang et al., 2023). Here, however, we observed accelerated tumorigenesis in Trp53Y217C/Y217C mice, but did not observe any evidence of DNE for spontaneous tumorigenesis in Trp53+/Y217C animals. Importantly, the fact that p53Y217C did not exhibit a DNE over the WT protein is consistent with the report that Li-Fraumeni patients carrying an heterozygous TP53Y220C mutation display a similar age of cancer onset than Li-Fraumeni patients with an heterozygous non-sense TP53 mutation (Xu et al., 2014). Furthermore, our evidence of an oncogenic GOF leading to aggressive metastatic tumors in Trp53Y217C/Y217C male mice is consistent with the oncogenic GOF attributed to p53Y220C in male patients with glioblastoma (Rockwell et al., 2021) or with experiments suggesting that p53Y220C expression in p53-null cells, or its overexpression in MCF-10A cells, may increase their migratory or invasive capacities (Pal et al., 2023; Zhou et al., 2022).
Our transcriptomic analyses suggested that the p53Y217C mutant might accelerate tumorigenesis by promoting inflammation, a hallmark of cancer (Hanahan, 2022) previously associated with a few other hotspot p53 mutants with oncogenic GOF (Agupitan et al., 2020; Behring et al., 2019; Ham et al., 2019; Zhao et al., 2024). Interestingly, the GSEA comparison of transcriptomes from Trp53Y217C/Y217C and Trp53-/- male thymic cells indicated differences related to inflammation and chemokine signaling, but also to mitochondria function and chromatin plasticity, and a link between inflammation, mitochondrial copper and epigenetic plasticity was recently demonstrated (Solier et al., 2023). Furthermore, the p53G245D or p53R273H mutants were proposed to accelerate tumorigenesis by promoting a chromosomal instability that would activate NC-NF-kB signaling and promote tumor cell metastasis (Zhao et al., 2024). Here we observed increased chromosomal instability in Trp53Y217C/Y217C fibroblasts, increased NC-NF-kB and inflammation-related signaling in Trp53Y217C/Y217C thymocytes, and increased tumor metastasis in Trp53Y217C/Y217C mice compared to their Trp53-/- counterparts. These data suggest that similar mechanisms might underlie the oncogenic properties of the p53Y217C, p53G245D and p53R273H mutants.
A striking and unexpected effect of the p53Y217C mutation was its severe impact on the perinatal viability of female mice, which led to observe only four Trp53Y217C/Y217C females for 75 Trp53Y217C/Y217C males at weaning from heterozygous intercrosses, or five Trp53Y217C/Y217C females for 111 Trp53Y217C/Y217C males when all weaned animals from relevant crosses were considered. The perinatal lethality of Trp53Y217C/Y217C females correlated with a high frequency (38.5%) of exencephalic females at E12.5-E16.5 embryonic ages. By comparison, the female to male ratio at weaning was 8/28 for Trp53-/- mice, and only 0-8% of exencephalic female Trp53-/- embryos were reported in similar genetic backgrounds (Armstrong et al., 1995; Donehower et al., 1992; Sah et al., 1995). These observations provide evidence of teratogenic effects for the p53Y217C mutant protein. Three other mouse p53 models were previously found to cause exencephaly at a higher frequency than a p53 null allele: Trp53NLS1, with 3 mutations at residues 316-318 affecting a nuclear localization signal and leading to a predominantly cytoplasmic localization of p53NLS1 in most cells (Regeling et al., 2011); Trp53N236S, a mouse model of TP53N239S, a recurrent but uncommon mutant in human cancers (Zhao et al., 2019); and Bim+/- Trp53-/- mice, combining p53 loss with an haploinsufficiency in the cytoplasmic proapoptotic regulator Bim/Bcl2l11 (Delbridge et al., 2019). The female-specific lethality of Trp53N236S mice was proposed to result from increased Xist expression, whereas a decrease in Xist expression was observed in Bim+/- Trp53-/- mice, suggesting distinct causes for neural tube defects (Delbridge et al., 2019; Zhao et al., 2019). We observed decreased Xist expression and an increased expression of X-linked genes in neurospheres from Trp53Y217C/Y217C females compared to WT females, whereas these genes were expressed at similar levels in neurospheres from Trp53Y217C/Y217C and Trp53-/- females. These results are not consistent with the mechanism proposed for exencephaly in the Trp53N236S mouse model, but might rather reflect a p53 LOF in Trp53Y217C/Y217C embryos. In addition, the analyses of the Trp53NLS1 and Bim+/- Trp53-/- mouse models make it tempting to speculate that, in female Trp53Y217C/Y217C embryos, the abundance of p53Y217C in the cytoplasm might perturb mitochondria function (Blandino et al., 2020) to further promote neural tube closure defects. Consistent with this possibility, p53 mutant proteins accumulating in the cytoplasm were reported to inhibit autophagy (Morselli et al., 2008), a key determinant for mitochondrial integrity (Rambold and Lippincott-Schwartz, 2011), and autophagy impairment may promote neural tube defects (Fimia et al., 2007; Ye et al., 2020).
Importantly, our data suggest that common mechanisms might contribute to the oncogenic effects accelerating tumorigenesis in Trp53Y217C/Y217C males and the teratogenic effects causing the perinatal lethality of many Trp53Y217C/Y217C females. Indeed, the RNAseq analysis of male thymocytes indicated that inflammation likely promotes oncogenesis in Trp53Y217C/Y217C males, and the administration of the anti-inflammatory drug supformin to pregnant mice increased the ratio of Trp53Y217C/Y217C weaned females in their progeny. Thus, the low female/male ratio observed for Trp53Y217C/Y217C weaned animals would likely result not only from aberrant X-chromosome inactivation in female embryos as in Trp53-/- animals (Delbridge et al., 2019), but also from inflammation. Presumably, a higher level of chromosomal instability in Trp53Y217C/Y217C cells might promote inflammation in Trp53Y217C/Y217C embryos (Rodier et al., 2009), and this might be more detrimental to females because Trp53Y217C/Y217C males would be protected by the anti-inflammatory effects of androgens (Ainslie et al., 2024; Bianchi, 2019; McNairn et al., 2019). Of note, we also observed that decreased Mdm4 levels increased the female/male ratio in Trp53Y217C/Y217C weaned mice. Because MDM4 overexpression was shown to promote genome instability and inflammation in cells independently of p53 (Carrillo et al., 2015; Liu et al., 2024), it is tempting to speculate that, as for supformin-treated mice, the improved survival of Trp53Y217C/Y217C female embryos in an Mdm4+/- background might result from decreased inflammation. Interestingly, in the offspring of human pregnancies at risk of early preterm delivery, an Interleukin-6 polymorphism was associated with a female-specific susceptibility to adverse neurodevelopmental outcome (Varner et al., 2020), suggesting that inflammation may also impact the development of human female embryos. Finally, our mating attempts with Trp53Y217C/Y217C mice indicated that Trp53Y217C/Y217C pregnant females exhibited dystocia, and parturition is considered to be a finely regulated inflammatory process (Zhang and Wei, 2021). Of note, dystocia was not observed in Trp53-/- mice, but was previously reported in pregnant females with a combined deficiency of p53 and FasL (Embree-Ku and Boekelheide, 2002). The fact that Trp53Y217C/Y217C females shared phenotypic traits with both Bim+/- Trp53-/- mice (neural tube defects) and FasL-/- Trp53-/- mice (dystocia) may seem relevant, because Bim and FasL are both regulators of apoptosis and autophagy that also regulate immune responses (Sionov et al., 2015; Taylor and Ng, 2018). Altogether, these data suggest that inflammation may cause accelerated tumorigenesis in Trp53Y217C/Y217C male mice and contribute to promote neural tube defects in Trp53Y217C/Y217C female embryos or dystocia in Trp53Y217C/Y217C pregnant females (Table S7).
In conclusion, we generated a mouse model expressing p53Y217C, the murine equivalent of human p53Y220C, and its analysis revealed that the gain-of-function of a hotspot mutant p53 may not be limited to oncogenic effects. This is an important notion to consider given the ever-expanding functions ascribed to p53 (Hu, 2009; Rakotopare and Toledo, 2023; Voskarides and Giannopoulou, 2023; Vousden and Lane, 2007). In addition, our results unveiled the potential relevance of supformin in obstetrics, which deserves further investigation.
Materials and methods
LSL-Y217C construct
We used mouse genomic Trp53 DNA from previous constructs, containing a portion of intron 1 with a LoxP-Stop-LoxP (LSL) cassette (Ventura et al., 2007) in which the puromycin-resistance gene was replaced by a neomycin-resistance gene (Simeonova et al., 2013). The point mutation (A to G) encoding a Tyr to Cys substitution (TAT to TGT) at codon 217, together with a silent mutation nearby creating a Ban II restriction site, were introduced by PCR directed mutagenesis by using primers Y217C-F and Y217C-R (See Table S8 for primer sequences). The resulting Trp53LSL-Y217C targeting vector was fully sequenced before use.
Targeting in ES Cells and Genotyping
129/SvJ embryonic stem (ES) cells were electroporated with the targeting construct linearized with Not I. Two recombinant clones, identified by long-range PCR and confirmed by internal PCR and Southern Blot, were injected into C57BL/6J blastocysts to generate chimeras, and germline transmission was verified by genotyping their offspring. In vivo excision of the LSL cassette was performed by breeding Trp53+/LSL-Y217C male mice with females carrying the PGK-Cre transgene (Lallemand et al., 1998) and genotyping their offspring. The Trp53Y217C (p53YC) mutation was routinely genotyped by PCR using primers c and d (Figure 1, Table S8) followed by BanII digestion. Tumorigenesis studies were performed on mouse cohorts resulting from ≥ 5 generations of backcrosses with C57BL6/J mice. For all experiments, mice housing and treatment were conducted according to the Institutional Animal Care and Use Committee of the Institut Curie (approved project #03769.02).
Cells and Cell Culture Reagents
Mouse embryonic fibroblasts (MEFs) isolated from 13.5-day embryos were cultured in a 5% CO2 and 3% O2 incubator, in DMEM GlutaMAX (Gibco), with 15% FBS (Biowest), 100 μM 2-mercaptoethanol (Millipore), 0.01 mM Non-Essential Amino-Acids, and penicillin/streptomycin (Gibco) for ≤ 6 passages. Cells were irradiated with a Cs γ-irradiator or treated for 24 hr with 10 μM Nutlin 3a (Sigma-Aldrich) or 1 μM Doxorubicin (Sigma-Aldrich). Neurospheres were prepared by isolating neural stem/progenitor cells (NPCs) from the lateral and median ganglionic eminences of E14.5 embryos. NPCs were cultured in a 5% CO2 incubator, in DMEM/F12 medium (with L-Glutamine, Invitrogen) supplemented with 1% B-27 (Invitrogen), 1% N2 (Invitrogen), 0.3% glucose (Invitrogen), 25 μg/ml insulin (Sigma-Aldrich), 20 ng/ml EGF (PeproTech), 10 ng/ml bFGF (PeproTech) and penicillin/streptomycin (Gibco). Neurospheres were dissociated once a week by Accutase treatment and mechanically, then seeded at 106 cells per 6 cm diameter dish.
Quantitative RT-PCR
Total RNA, extracted using NucleoSpin RNA II (Macherey-Nagel), was reverse transcribed using SuperScript IV (Invitrogen). Real-time quantitative PCRs were performed as previously described (Simeonova et al., 2012), on an ABI PRISM 7500 using Power SYBR Green (Applied Biosystems). Primer sequences are reported in Table S8.
Western Blots
Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% deoxycholic acid, 0.1% SDS, 1% NP-40) supplemented with Protease inhibitors cocktail (Roche) and 1 mM PMSF (Sigma). Whole-cell extracts were sonicated three times for 10 s and centrifuged at 13 000 rpm for 30 min to remove cell debris. Protein lysate concentration was determined by BCA assay (Thermo Scientific) and 30 μg of each lysate was fractionated by SDS–PAGE on a 4-12% polyacrylamide gel and transferred onto polyvynilidene difluoride (PVDF) membranes (Amersham). Membranes were incubated with antibodies raised against Mdm2 (MDM2-4B2, Abcam, 1/500), p53 (CM-5, Novocastra, 1/2000), p21 (F5, Santa Cruz Biotechnology, 1/200) and actin (actin-HRP sc47778, Santa Cruz Biotechnology, 1/5000). Chemiluminescence revelation of western blots was achieved with the SuperSignal West Dura (Perbio).
ChIP Assay
ChIP analysis was performed as previously described (Simeonova et al., 2013). p53-DNA complexes were immunoprecipitated from total extracts by using 50 μg of a polyclonal antibody against p53 (FL-393, Santa Cruz Biotechnology) and 300 μg of sonicated chromatin. Rabbit IgG (Abcam) was used for control precipitation. Quantitative PCR was performed on ABI PRISM 7500. Primer sequences are reported in Table S8.
Cell Fractionation Assay
Cells were lysed in hypotonic lysis buffer (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM Mgcl2, 0.3% NP-40, 10% glycerol) on ice for 10 min, then centrifuged at 4°C for 3 min at 1000g. The supernatant was recovered as the cytoplasmic fraction, and the pellet was incubated in a modified Wuarin-Schibler buffer (10 mM Tris-HCl pH 7.0, 4 mM EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40) on ice for 5 min, vortexed, incubated on ice for 10 min, then centrifuged at 4°C for 3 min at 1000g. The supernatant was recovered as the nucleoplasmic fraction, and the pellet was washed, then incubated in a nuclear lysis buffer (20 mM Tris pH 7.5, 150 mM KCl, 3 mM MgCl2, 0.3% NP-40, 10% glycerol) on ice for 5 min, sonicated, then centrifuged at 13000 rpm at 4°C and the supernatant was recovered as the chromatin fraction. All buffers were supplemented with Protease inhibitors cocktail (Roche). Cellular fractions were analyzed by western blots with antibodies against p53 (AF-1355, R&D systems, 1/600), Tubulin (ab15568, Abcam, 1/1000), Nup98 (ab50610, Abcam, 1/1000) and histone H3 (ab1791, Abcam, 1/1000). Chemiluminescence revelation was achieved with SuperSignal West Pico or Femto (Thermoscientific) and analyzed with a ChemiDoc imaging system (Bio-Rad).
Immunofluorescence
MEFs were cultured on collagen-coated coverslips, treated with 10 μM Nutlin 3a (Sigma-Aldrich) for 24 hr and analyzed. Coverslips were stained with rabbit anti-p53 FL-393 (Santa Cruz Biotechnology, 1/50), mouse anti-actin primary antibody and with Alexa Fluor 647 anti-Rabbit and Alexa Fluor 488 anti-Mouse secondary antibodies (Molecular Probes). DNA was counterstained with DAPI. Images were captured on an epifluorescence microscope using equal exposure times for all images for each fluor.
Cell-Cycle Assay
Log phase cells were irradiated at room temperature (RT) with a Cs γ-irradiator at doses of 3 or 12 Gy, incubated for 24 hr, then pulse labeled for 1 hr with BrdU (10 μM), fixed in 70% ethanol, double stained with FITC anti-BrdU and propidium iodide, and analyzed by flow cytometry with a BD Biosciences FACSort and the FlowJo software.
Apoptosis Assay
Six to eight weeks-old mice were left untreated or submitted to 10 Gy whole-body ɣ-irradiation. Mice were sacrificed 4 hr later and thymi were extracted. Thymocytes were recovered by filtration through a 70 μm smash, stained with Annexin V-FITC Apoptosis detection kit (Abcam) and propidium iodide, then analyzed with a LSRII FACS machine. Data were analyzed using Flowjo software.
Metaphase spread preparation and analysis
Primary MEFs (at passage 4 for all genotypes) were treated with 0.1 mM nocodazole for 3 h to arrest cells in metaphase, then submitted to hypotonic shock (75 mM KCl), fixed in a (3:1) ethanol/acetic acid solution, dropped onto glass slides, then air-dried slides were stained with Giemsa to score for chromosome aberrations. Images were acquired using a Zeiss Axiophot (X63) microscope.
Histology
Organs were fixed in formol 4% for 24 hr, then ethanol 70%, and embedded in paraffin wax. Serial sections of 3 μm were stained as described (Simeonova et al., 2013), with hematoxylin and eosin using standard procedures.
RNA-Seq analysis
Total RNA was extracted from the thymi of 8 weeks-old asymptomatic male mice using nucleospin RNA II (Macherey-Nagel). The quality of RNA was checked with Bioanalyzer Agilent 2100 and RNAs with a RIN (RNA integrity number) ≥ 7 were retained for further analysis. RNA was depleted from ribosomal RNA, then converted into cDNA libraries using a TruSeq Stranded Total Library preparation kit (Illumina). Paired-end sequencing was performed on an Illumina MiSeq platform. Reads were mapped to the mouse genome version GRCm38 and counted on gene annotation gencode.vM18 with featureCounts (Liao et al., 2014). Differentially expressed genes with an adjusted p-value < 0.05 were identified using the DESeq2 R package (Love et al., 2014).
Gene Ontology analysis
Gene ontology analysis of differentially expressed genes was performed by using the GOrilla (Technion) software as previously described (Rakotopare et al., 2023). Enrichment analyses were carried out by comparing the list of 192 differentially expressed genes between Trp53Y217C/Y217C and Trp53-/- thymi to the full list of genes (background), with ontology searches for biological processes and default P-value settings (10−3).
Gene set enrichment analysis
Gene set enrichment analysis was performed by using the GSEA software with canonical pathway gene sets from the Mouse Molecular Signature Database (MSigDB) (Subramanian et al., 2005). Gene sets with a false discovery rate (FDR) q-value < 0.25 were regarded as potentially relevant. The best candidates, with an FDR q-value < 0.01, exhibited normalized enrichment scores (NES) > 1.91 and nominal (NOM) P-values <0.003.
Oral gavage of pregnant females
Trp53+/Y217C female mice were mated with Trp53Y217C/Y217C males, then mice with a vaginal plug on the next day were separated from males and weighted every other day to confirm pregnancy. On the 10th and 11th days post-coitum, pregnant mice received 5 mg/kg of supformin (in a PBS solution) by oral gavage with flexible gauge feeding tubes, then their pups were genotyped at weaning.
Statistical analyses
Unless noted otherwise, we used a Student’s t test to analyze differences between two groups of values. For the proportions of mice at weaning, the observed mouse count was compared to the expected count according to Mendel’s distribution and a Chi-square (χ2) test, and a Fischer’s test was applied to compare frequencies of mutant females or female to male ratios. Fischer’s tests were also used to analyze frequencies of chromosome rearrangements in fibroblasts. Survival curves were analyzed with log-rank Mantel-Cox tests. Analyses were performed by using GraphPad Prism, and values of P ≤ 0.05 were considered significant.
Data availability
RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) under the accession code GSE248936. All other data are available within the article and its supplementary information.
Supplementary figures

Protein sequence alignment showing homology between mouse p53 Tyrosine 217 and human p53 Tyrosine 220.
Portions of the DNA binding domains from the mouse (residues 208-228) and human (residues 211-231) p53 proteins are shown, with identical residues in bold, and mouse Tyrosine 217 and human Tyrosine 220 in red.

Uncropped images of the western blot presented in Figure 2A.
All images are from the same blot, cut in two below the 35 kDa marker before incubation with the indicated antibodies.

Uncropped images of the fractionation assays presented in Figure 2C.
Chemiluminescence and colorimetric scans obtained with a ChemiDoc imaging system (Bio-Rad) were superposed to show the entire membranes, ladder lanes (λ), and chemiluminescence signals from subcellular fractions.

Cell cycle arrest responses of Trp53+/+, Trp53Y217C/Y217C and Trp53-/- mouse embryonic fibroblasts.
Asynchronous MEFs were exposed to 0-12 Gy ɣ-irradiation, then after 24 hr cells were labelled with BrdU for 1 hr and analyzed by FACS. A typical experiment for cells of each genotype and condition is shown, with % cells in G1, S or G2/M mentioned in each panel.

Apoptotic responses of Trp53+/+, Trp53-/- and Trp53Y217C/Y217C thymocytes.
Mice were ɣ-irradiated (or not) and their thymocytes were recovered and analyzed by FACS after annexin V-FITC staining. A typical experiment for cells of each genotype and condition is shown. Numbers indicate % cells either alive (live), early apoptotic (early) or mid to late apoptotic (mid+late).

Comparison of stress responses in WT, Trp53+/Y217C and Trp53+/- cells.
(A) Transactivation of the classical p53 target genes Cdkn1a/p21, Mdm2 and Pmaip1/Noxa in response to Nutlin or Doxorubicin. WT, Trp53+/Y217C and Trp53+/- MEFs were treated or not with 10 μM Nutlin 3a (Nut) or 1 μM Doxorubicin (Doxo) for 24 h, then mRNAs were quantified in ≥ 4 independent experiments using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in unstressed WT cells assigned a value of 1. For each condition and gene, a DNE would lead to significant decrease in transactivation in Trp53+/Y217C MEFs compared to both WT and Trp53+/- MEFs, a result that was not observed. (B) Cell cycle arrest responses to ɣ-irradiation. Asynchronous cell populations of WT, Trp53+/Y217C and Trp53+/- MEFs were analyzed 24 hr after 0, 3 or 12 Gy ɣ-irradiation, in 3 independent experiments. The comparison of cells submitted to identical irradiation doses revealed similar arrest responses in cells of all genotypes. (C) Apoptotic responses to ɣ-irradiation. WT, Trp53+/Y217C and Trp53+/- MEFs age-matched mice were left untreated or submitted to 10 Gy whole-body ɣ-irradiation, then sacrificed after 4 hr and their thymocytes were stained with Annexin V-FITC and analyzed by FACS, in 2 independent experiments. The percentage of apoptotic cells was significantly higher in irradiated WT thymocytes compared to irradiated Trp53+/Y217C or Trp53+/- cells, whereas Trp53+/Y217C and Trp53+/- cells were not significantly different. **P<0.01, *P<0.05, ns: non-significant by Student’s t test.

Evidence of aberrant chromosome X inactivation in Trp53Y217C/Y217C and Trp53-/- female embryos.
The expression of Xist and 3 X-linked genes (Maob, Usp9x and Pls3) was quantified in neurospheres from 2 Trp53+/+, 5 Trp53Y217C/Y217C and 3 Trp53-/- female embryos by using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in WT neurospheres assigned a value of 1. *P<0.05, °P=0.09, ns: non-significant by Student’s t tests.

Trp53+/Y217C and Trp53+/- mice exhibit similar tumor onset and spectra.
No significant difference was observed between heterozygous Trp53+/- and Trp53+/Y217C mice, neither in spontaneous tumor onset and survival (A), nor in tumor spectra (B); n=cohort size. Mice of both sexes were included in this study.

Example of a Trp53Y217C/Y217C mouse with a thymic lymphoma and lymphomatous infiltrates in the liver and kidney.
H&E staining of sections from the thymus (top), liver (middle) and kidney (bottom) of a Trp53Y217C/Y217C male mouse, showing tumor lymphocytes (TL) in the thymus and lymphocyte infiltrates (LI) in the liver and kidney, near blood vessels (BV). Hepatocytes (H), kidney tubules (TB) and a glomerulus (G) are also indicated.

RNA-seq analysis from the thymi of 8 weeks-old Trp53+/+, Trp53Y217C/Y217C and Trp53-/- male mice.
(A) Heat-Map plot, with 717 differentially expressed genes suggestive of a loss of function (LOF), a separation of function (SOF) or a gain of function (GOF) for the p53Y217C mutant, ranked according to log2 fold change (n=number of genes). (B) Evidence of LOF in Trp53Y217C/Y217C cells for genes encoding Puma, p21 and Zmat3. Data from 3 mice per genotype. ***P<0.001, **P<0.01, *P<0.05, °P=0.07, ns: non-significant by Student’s t tests.

Gene ontology analysis of differentially expressed genes.
The 192 differentially expressed genes (DEGs) between Trp53-/- and Trp53Y217C/Y217C thymocytes (Fig. 5A) were analyzed with the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla). Out of 192 genes, 141 were associated with a GO term. For each GO term, enrichment was calculated by comparing with the full list of 19759 genes associated with a GO term. For example, genes with GO term #0071621 (granulocyte chemotaxis) represent 79/19759 genes associated with a GO term, but 8/141 of the identified DEGs, which represents a 14.19-fold enrichment.

Gene set enrichment analysis (GSEA) of transcriptomes from Trp53Y217C/Y217C (Y220C) and Trp53-/- (KO) thymic cells: examples of GSEA enrichment plots.
Examples of GSEA enrichment plots indicating differences in immune responses (A), mitochondrial function (B) and chromatin plasticity (C) are shown.

GSEA enrichment plot showing increased NC-NF-kB signaling in Trp53Y217C/Y217C cells.
Transcriptomes from Trp53Y217C/Y217C (Y220C) and Trp53-/- (KO) thymic cells were compared by Gene Set Enrichment Analysis.
Supplementary tables

Viability of Mdm2 or Mdm4 loss in a Trp53Y217C/Y217C background.
Mouse distributions from the indicated crosses were determined at weaning. As for Trp53+/Y217C intercrosses, these crosses yielded a deficit in weaned Trp53Y217C/Y217C females compared to Trp53Y217C/Y217C males (4/75 from Trp53+/Y217C intercrosses (Figure 3A); 0/9 from crosses between Mdm4+/- Trp53+/Y217C and Mdm4+/- Trp53Y217C/Y217C mice; and 0/5 from mating Mdm2+/- Trp53+/Y217C mice with Mdm2+/- Trp53Y217C/Y217C or Mdm2-/- Trp53Y217C/Y217C animals). Trp53Y217C/Y217C females over Mdm4 or Mdm2 deficient or haplo-insufficient backgrounds were also less frequent than their male counterparts, but the female/male ratio for Trp53Y217C/Y217C mice over a Mdm4+/- background (4/15) was significantly increased (P=0.04 when 4/75 and 4/15 ratios are compared in a Fischer’s test). Whether or not the female/male ratios for Trp53Y217C/Y217C mice were significantly increased over Mdm4-/- (1/6), Mdm2-/- (1/11) or Mdm2+/- (1/11) backgrounds remained uncertain due to limited animal numbers.

Evidence of dystocia in pregnant Trp53Y217C/Y217C females.
Results of the mating of two (a and b) Trp53 Y217C/Y217C females (F) with a Trp53+/Y217C male (M) are shown. Both females were rapidly pregnant after encountering a male, but had to be sacrificed due to extended labor and pain during their first (female a) or third (female b) delivery.


Differentially expressed genes between WT, Trp53Y217C/Y217C (YC) and Trp53-/- (KO) thymocytes from age-matched animals.
Most differentially expressed genes correspond to a loss of function (LOF) in the p53Y217C mutant (categories 1 and 2, see Figure S10A), but genes corresponding to a separation of function (SOF, categories 3 and 4) or a gain of function (GOF, categories 5 and 6) were also observed.

A De-Seq analysis of RNA seq data from Trp53-/- (KO) and Trp53Y217C/Y217C (YC) thymi revealed 192 differentially expressed genes.
As shown in Figure 5B, 107 genes (in bold) were less expressed and 85 genes were more expressed in Trp53Y217C/Y217C cells compared to Trp53-/- cells.

Ccl17, Ccl9, Ccr3, Cxcl10, S100a8 and S100a9 are associated with GO terms of white blood cell migration/chemotaxis and inflammation.

Distribution of weaned pups after mating Trp53+/Y217C females with Trp53Y217C/Y217C males and oral gavage of pregnant females with supformin.
Due to the gavage of pregnant mothers, all the pups born in this experiment were exposed to supformin in utero (SIU+).

Effects of the Trp53Y217C mutation: a summary.
The comparison between Trp53-/- and Trp53Y217C/Y217C mice is presented. The phenotypes observed in Trp53-/- male (M) and female (F) mice result from p53 loss of function (LOF), whereas those observed in Trp53Y217C/Y217C mice result from p53 LOF as well as additional effects (gain of function (GOF) in red). The + signs denote the presence of a phenotype. Xi: X chromosome inactivation.

Primers used in this study.
Acknowledgements
This project was supported by grants attributed to F.T., from the Ligue Nationale Contre le Cancer, the Fondation ARC pour la recherche sur le Cancer and the Gefluc. S.J., E.E. and J.R. were PhD fellows of the Ministère de la Recherche, supervised by F.T. (S.J., J.R.) or B.B. (E.E.). S.J. and E.E. received additional support from the Fondation ARC. M.G. was paid by European Research Council 875532-Prostator-ERC-2019-PoC attributed to A.M. For some experiments, S.J. and V.V. received technical assistance from C. Bouyer and R. Bourimi. We thank the following members of the Institut Curie platforms: I. Grandjean, H. Gautier, C. Daviaud, M. Garcia, D. Andreau, M. Verlhac and A. Fosse (animal facility); S. Baulande and S. Lameiras (NGS); M. Huerre, A. Nicolas and R. Leclere (histopathology); Z. Maciorowski, A. Viguier and S. Grondin (flow cytometry).
Additional information
Author Contributions
Conceptualization: F.T.; investigation: S.J., E.E., J.R., I.S, V.L., V.V., M.L., A.F., B.B., F.T.; formal analysis: M.G., B.B., F.T.; resources: T.C., R.R., A.M.; supervision, writing and visualization: F.T., B.B; project administration and funding acquisition: F.T.
References
- P53: A Guardian of Immunity Becomes Its Saboteur through MutationInt J Mol Sci 21:3452https://doi.org/10.3390/ijms21103452
- RISING STARS: Androgens and immune cell functionJ Endocrinol 261:e230398https://doi.org/10.1530/JOE-23-0398
- Context is everything: extrinsic signalling and gain-of-function p53 mutantsCell Death Discov 6:16https://doi.org/10.1038/s41420-020-0251-x
- High-frequency developmental abnormalities in p53-deficient miceCurr Biol 5:931–936https://doi.org/10.1016/s0960-9822(95)00183-7
- Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor developmentGenes Dev 32:1420–1429https://doi.org/10.1101/gad.314286.118
- Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activityOncogene 34:2943–2948https://doi.org/10.1038/onc.2014.230
- Transcriptional regulation by p53Cold Spring Harb Perspect Biol 2:a000935https://doi.org/10.1101/cshperspect.a000935
- Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophagesMolec Genet Genomic Med 7:e1001https://doi.org/10.1002/mgg3.1001
- The Anti-Inflammatory Effects of TestosteroneJ Endocr Soc 3:91–107https://doi.org/10.1210/js.2018-00186
- Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer diseaseSemin Cell Dev Biol 98:105–117https://doi.org/10.1016/j.semcdb.2019.05.011
- A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignanciesScience 365:599–604https://doi.org/10.1126/science.aax3649
- TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics DataHum Mutat 37:865–876https://doi.org/10.1002/humu.23035
- Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in miceCell Death Differ https://doi.org/10.1038/s41418-023-01250-w
- Mdmx promotes genomic instability independent of p53 and Mdm2Oncogene 34:846–856https://doi.org/10.1038/onc.2014.27
- Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube DefectsCell Rep 27:442–454https://doi.org/10.1016/j.celrep.2019.03.048
- Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivoSci Adv 10:eadk1835https://doi.org/10.1126/sciadv.adk1835
- Gain of function mutations in p53Nat Genet 4:42–46https://doi.org/10.1038/ng0593-42
- Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumoursNature 356:215–221https://doi.org/10.1038/356215a0
- First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutationJ Clin Oncol 40:suppl 3003https://doi.org/10.1200/JCO.2022.40.16_suppl.3003
- GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene listsBMC Bioinformatics 10:48https://doi.org/10.1186/1471-2105-10-48
- Absence of p53 and FasL has sexually dimorphic effects on both development and reproductionExp Biol Med (Maywood) 227:545–553https://doi.org/10.1177/153537020222700720
- The epigenetic progenitor origin of human cancerNat Rev Genet 7:21–33https://doi.org/10.1038/nrg1748
- Ambra1 regulates autophagy and development of the nervous systemNature 447:1121–1125https://doi.org/10.1038/nature05925
- . mdmx is a negative regulator of p53 activity in vivoCancer Res 62:3221–3225
- Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutationsNat Genet 57:140–153https://doi.org/10.1038/s41588-024-02039-4
- p53 tetramerization: at the center of the dominant-negative effect of mutant p53Genes Dev 34:1128–1146https://doi.org/10.1101/gad.340976.120
- TP53 Y220C mutations in patients with myeloid malignanciesLeukemia & Lymphoma 65:1511–1515https://doi.org/10.1080/10428194.2024.2363440
- Inflammation and Cancer: Triggers, Mechanisms, and ConsequencesImmunity 51:27–41https://doi.org/10.1016/j.immuni.2019.06.025
- Pregnancy-associated uterine granulated metrial gland cells in mutant and transgenic miceAm J Reprod Immunol 35:501–509https://doi.org/10.1111/j.1600-0897.1996.tb00049.x
- Somatic TP53 Mutations in the Era of Genome SequencingCold Spring Harb Perspect Med 6:a026179https://doi.org/10.1101/cshperspect.a026179
- TP53 gain-of-function mutation promotes inflammation in glioblastomaCell Death Differ 26:409–425https://doi.org/10.1038/s41418-018-0126-3
- Hallmarks of Cancer: New DimensionsCancer Discovery 12:31–46https://doi.org/10.1158/2159-8290.CD-21-1059
- Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesisCell Death Differ 20:898–909https://doi.org/10.1038/cdd.2013.17
- p53 mutations in human cancersScience 253:49–53https://doi.org/10.1126/science.1905840
- The role of p53 gene family in reproductionCold Spring Harb Perspect Biol 1:a001073https://doi.org/10.1101/cshperspect.a001073
- p53 regulates maternal reproduction through LIFNature 450:721–724https://doi.org/10.1038/nature05993
- p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutantCancer Metab 6:18https://doi.org/10.1186/s40170-018-0191-6
- Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null miceOncogene 23:7644–7650https://doi.org/10.1038/sj.onc.1207793
- Tumor spectrum analysis in p53-mutant miceCurr Biol 4:1–7https://doi.org/10.1016/s0960-9822(00)00002-6
- Structural basis for understanding oncogenic p53 mutations and designing rescue drugsProc Natl Acad Sci U S A 103:15056–15061https://doi.org/10.1073/pnas.0607286103
- Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53Nature 378:206–208https://doi.org/10.1038/378206a0
- The gut microbiome switches mutant p53 from tumour-suppressive to oncogenicNature 586:133–138https://doi.org/10.1038/s41586-020-2541-0
- Recursive Feature Elimination-based Biomarker Identification for Open Neural Tube DefectsCurr Genomics 23:195–206https://doi.org/10.2174/1389202923666220511162038
- A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasiaCell 71:587–597https://doi.org/10.1016/0092-8674(92)90593-2
- Mutant p53: it’s not all one and the sameCell Death Differ 29:983–987https://doi.org/10.1038/s41418-022-00989-y
- Interactions of mutant p53 with DNA: guilt by associationOncogene 26:2185–2190https://doi.org/10.1038/sj.onc.1210312
- Mutant p53 partners in crimeCell Death Differ 25:161–168https://doi.org/10.1038/cdd.2017.185
- A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary ConservationMol Cell 71:178–190https://doi.org/10.1016/j.molcel.2018.06.012
- Tumor Cell Metabolism: Cancer’s Achilles’ HeelCancer Cell 13:472–482https://doi.org/10.1016/j.ccr.2008.05.005
- Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinaseTransgenic Res 7:105–112https://doi.org/10.1023/a:1008868325009
- Enhanced inflammatory response in neural tubes of embryos derived from diabetic mice exposed to a teratogenJ of Neuroscience Research 75:554–564https://doi.org/10.1002/jnr.20006
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic featuresBioinformatics 30:923–930https://doi.org/10.1093/bioinformatics/btt656
- MDM4 was associated with poor prognosis and tumor-immune infiltration of cancersEur J Med Res 29:79https://doi.org/10.1186/s40001-024-01684-z
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biol 15:550https://doi.org/10.1186/s13059-014-0550-8
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature 362:847–849https://doi.org/10.1038/362847a0
- Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4Cell Death Differ 13:927–934https://doi.org/10.1038/sj.cdd.4401912
- Mutant p53 elicits context-dependent pro-tumorigenic phenotypesOncogene 41:444–458https://doi.org/10.1038/s41388-021-01903-5
- Female-biased embryonic death from inflammation induced by genomic instabilityNature 567:105–108https://doi.org/10.1038/s41586-019-0936-6
- Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse developmentMol Cell Biol 22:5527–5538https://doi.org/10.1128/MCB.22.15.5527-5538.2002
- Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53Nature 378:203–206https://doi.org/10.1038/378203a0
- Mutant p53 protein localized in the cytoplasm inhibits autophagyCell Cycle 7:3056–3061https://doi.org/10.4161/cc.7.19.6751
- Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutantsNPJ Breast Cancer 9:78https://doi.org/10.1038/s41523-023-00582-7
- Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53Nat Genet 29:92–95https://doi.org/10.1038/ng714
- Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53Cold Spring Harb Perspect Med 7:a026054https://doi.org/10.1101/cshperspect.a026054
- A systematic approach identifies p53-DREAM pathway target genes associated with blood or brain abnormalitiesDis Model Mech 16:dmm050376https://doi.org/10.1242/dmm.050376
- p53 in the Molecular Circuitry of Bone Marrow Failure SyndromesInt J Mol Sci 24:14940https://doi.org/10.3390/ijms241914940
- Mechanisms of mitochondria and autophagy crosstalkCell Cycle 10:4032–4038https://doi.org/10.4161/cc.10.23.18384
- Mice defective in p53 nuclear localization signal 1 exhibit exencephalyTransgenic Res 20:899–912https://doi.org/10.1007/s11248-010-9468-4
- Sex- and Mutation-Specific p53 Gain-of-Function Activity in GliomagenesisCancer Research Communications 1:148–163https://doi.org/10.1158/2767-9764.CRC-21-0026
- Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretionNat Cell Biol 11:973–979https://doi.org/10.1038/ncb1909
- A subset of p53-deficient embryos exhibit exencephalyNat Genet 10:175–180https://doi.org/10.1038/ng0695-175
- TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functionseLife :e17929https://doi.org/10.7554/eLife.17929
- Mutant mice lacking the p53 C-terminal domain model telomere syndromesCell Rep 3:2046–2058https://doi.org/10.1016/j.celrep.2013.05.028
- Fuzzy Tandem Repeats Containing p53 Response Elements May Define Species-Specific p53 Target GenesPLoS Genet 8:e1002731https://doi.org/10.1371/journal.pgen.1002731
- Regulation of Bim in Health and DiseaseOncotarget 6:23058–23134https://doi.org/10.18632/oncotarget.5492
- A druggable copper-signalling pathway that drives inflammationNature 617:386–394https://doi.org/10.1038/s41586-023-06017-4
- Mutant p53 oncogenicity: dominant-negative or gain-of-function?Carcinogenesis 41:1635–1647https://doi.org/10.1093/carcin/bgaa117
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProc Natl Acad Sci USA 102:15545–15550https://doi.org/10.1073/pnas.0506580102
- Interactions between the otitis media gene, Fbxo11, and p53 in the mouse embryonic lungDisease Models & Mechanisms :dmm.022426https://doi.org/10.1242/dmm.022426
- Negative regulators that mediate ocular immune privilegeJ Leukoc Biol https://doi.org/10.1002/JLB.3MIR0817-337R
- A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory networkCancer Cell 9:273–285https://doi.org/10.1016/j.ccr.2006.03.014
- Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with AilanthoidolInt J Mol Sci 23:5102https://doi.org/10.3390/ijms23095102
- Sex-Specific Genetic Susceptibility to Adverse Neurodevelopmental Outcome in Offspring of Pregnancies at Risk of Early Preterm DeliveryAm J Perinatol 37:281–290https://doi.org/10.1055/s-0039-1678535
- In vivo activation of the p53 pathway by small-molecule antagonists of MDM2Science 303:844–848https://doi.org/10.1126/science.1092472
- Restoration of p53 function leads to tumour regression in vivoNature 445:661–665https://doi.org/10.1038/nature05541
- Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53Nucleic Acids Res 35:2093–2104https://doi.org/10.1093/nar/gkm099
- The Role of TP53 in Adaptation and EvolutionCells 12:512https://doi.org/10.3390/cells12030512
- p53 in health and diseaseNat Rev Mol Cell Biol 8:275–283https://doi.org/10.1038/nrm2147
- Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival and metastasis of a broad range of cancer cellsCancer Discov https://doi.org/10.1158/2159-8290.CD-23-0402
- Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In VivoCancer Research 82:1926–1936https://doi.org/10.1158/0008-5472.CAN-21-3376
- Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutationsSci Rep 4:4223https://doi.org/10.1038/srep04223
- Rare mutations in the autophagy-regulating gene AMBRA1 contribute to human neural tube defectsHum Mutat 41:1383–1393https://doi.org/10.1002/humu.24028
- Role of Decidual Natural Killer Cells in Human Pregnancy and Related Pregnancy ComplicationsFront Immunol 12:728291https://doi.org/10.3389/fimmu.2021.728291
- p53 Mutant p53 N236S Induces Neural Tube Defects in Female EmbryosInt J Biol Sci 15:2006–2015https://doi.org/10.7150/ijbs.31451
- Folic Acid Protects against Lipopolysaccharide-Induced Preterm Delivery and Intrauterine Growth Restriction through Its Anti-Inflammatory Effect in MicePLoS ONE 8:e82713https://doi.org/10.1371/journal.pone.0082713
- Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA responseNat Commun 15:180https://doi.org/10.1038/s41467-023-44239-2
- Triptolide promotes degradation of the unfolded gain-of-function Tp53R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancerTransl Lung Cancer Res 11:802–816https://doi.org/10.21037/tlcr-22-312
Article and author information
Author information
Version history
- Sent for peer review:
- Preprint posted:
- Reviewed Preprint version 1:
- Reviewed Preprint version 2:
Copyright
© 2024, Jaber et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
- views
- 299
- downloads
- 10
- citations
- 0
Views, downloads and citations are aggregated across all versions of this paper published by eLife.